This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effects of Keppra on Thinking, Emotions, and Balance in Elderly Healthy Volunteers

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by University Hospitals Cleveland Medical Center.
Recruitment status was:  Recruiting
Michael Schoenberg, Ignacio Pita, Kyra Dawson
Information provided by:
University Hospitals Cleveland Medical Center Identifier:
First received: September 16, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
Epilepsy is a common disorder with an incidence of about 6 per 1000. The incidence progressively increases above age 50. By age 75, the incidence is two to three fold compared with any age group. Unfortunately, older individuals are especially at risk to incur significant side effects to anti-epileptic drugs. A newer anti-epileptic drug may markedly improve seizure management in older individuals as it is removed by the kidneys and not the liver and does not interact with other medications. We expect it to be tolerated well in terms of effects on memory, thinking,balance, and walking. The current study assesses the side effects of levetiracetam in healthy volunteers aged 65 to 80. Use of healthy volunteers eliminates the effects of seizures on the outcome.

Condition Intervention
Epilepsy Drug: Levetiracetam (Keppra)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Cross-Over Study of the Cognitive and Mood Effects of KEPPRA (Levetiracetam) Tablets in Healthy Older Adults.

Resource links provided by NLM:

Further study details as provided by University Hospitals Cleveland Medical Center:

Primary Outcome Measures:
  • 1.Objective Neuropsyhological testing
  • 2.Subjective Behavioral Measures
  • 3.Balance Measures

Estimated Enrollment: 40
Study Start Date: March 2004
Estimated Study Completion Date: September 2005
  Show Detailed Description


Ages Eligible for Study:   65 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Study Population Inclusion Criteria

A subject will be eligible for inclusion in this study only if all of the following criteria apply. A subject must:

  1. Provide a copy of their medical records from a primary care physician for the past year to assist in establishing the patient’s current health status. The study physician will review PCP medical records to assure participants meet the study inclusion/exclusion criteria.
  2. Be a healthy adult age 65 to 80 years old. Healthy subjects are defined as individuals who are free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, neurological and psychiatric disease as determined by history and physical examination.
  3. Be, in the investigator's opinion, compliant, able to follow the investigator's instructions and visit the clinic on schedule, cooperative and reliable.
  4. Subjects must score within –1.0 standard deviations of the mean performance of healthy individuals on the neuropsychological tests at screen (week –2). Subjects must have a reading equivalency of 8th grade. Participants must also have a MMSE score of 28. (Bravo & Herbert, 1997; Crum et al., 1993). Finally, participants must score a 45 or better on the Berg Balance Test at screening (week –2) to be included in the study.
  5. Sign an informed consent.
  6. For participants living alone, provide the name and number of at least one friend or family member that study personnel may contact in the unlikely event that study personnel are unable to contact the patient by phone past 48 hours of a scheduled phone contact time which was not planned.

Exclusion Criteria:

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply. A subject must not:

  1. Have a history of any type of epilepsy.
  2. Be taking any concomitant medications that are or any concomitant medications that may alter cognitive function or mood.
  3. Have a current or past history of drug or alcohol abuse or dependence. Have a positive urine toxicology test at screen.
  4. Have a history and clinical finding of a progressive encephalopathy including CNS tumors of all types.
  5. Have a serious illness in the past month that may confound the interpretation of study results.
  6. Be on anticoagulation with warfarin.
  7. Have experienced a prior adverse reaction or hypersensitivity to either study medication or to related compounds.
  8. Be currently participating in another clinical study in which the subject will be exposed to an investigational or a non-investigational drug or device.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00221988

Contact: Mary Ann Werz, M.D., Ph,D. 216-844-3717
Contact: Mike R Schoenberg, Ph.D. 216-844-5820

United States, Ohio
University Hospitals of Cleveland Recruiting
Cleveland, Ohio, United States, 44106
Contact: Mary Ann Werz, M.D., Ph.D.    216-844-3100   
Contact: Mary Ann Werz, M.D.    216-844-3717   
Principal Investigator: Mary Ann Werz, M.D., Ph.D.         
Principal Investigator: Mike R sCHOENBERG, Ph.D.         
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Michael Schoenberg, Ignacio Pita, Kyra Dawson
Principal Investigator: Mary Ann Werz, M.D., Ph.D. University Hospitals Cleveland Medical Center
Principal Investigator: Mike R Schoenberg, Ph.D. University Hospitals Cleveland Medical Center
  More Information Identifier: NCT00221988     History of Changes
Other Study ID Numbers: UCB MRS001
UHC 06-04-52
Study First Received: September 16, 2005
Last Updated: September 16, 2005

Keywords provided by University Hospitals Cleveland Medical Center:
Health Outcome

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Nootropic Agents
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs processed this record on June 23, 2017